Since discovered in 1983 in neuroblastoma (1, 3), the oncogenic effect of N-MYC has been demonstrated both in various neuronal [e.g., glioblastoma (29), medulloblastoma (30), astrocytoma (31)], and nonneuronal [e.g., prostate cancers (32), breast cancers (33), hematologic malignancies (34), pancreatic tumors (35), Wilms tumors (36), hepatocellular carcinoma (37), rhabdomyosarcoma (38), ovarian cancers (39)] tumors. Here, MYCN is linked to Wilms tumor.